awmsg logo



levodopa-carbidopa intestinal gel (Duodopa®)


Reference No. 3397

Publication date:
23/03/2018


Appraisal information

levodopa-carbidopa intestinal gel (Duodopa®) 20 mg/ml + 5 mg/ml intestinal gel


Company: AbbVie Ltd
BNF category: Central nervous system
NMG meeting date: 04/10/2017
AWMSG meeting date: 14/03/2018
   
   
Submission Type: Resubmission
Status: Recommended with restrictions
Advice No: 0518
Ratification by Welsh Government: 22/03/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Levodopa-carbidopa intestinal gel (Duodopa®) is recommended as an option for restricted use within NHS Wales. Levodopa-carbidopa intestinal gel (Duodopa®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results: • Patients not eligible for deep brain stimulation. Levodopa-carbidopa intestinal gel (Duodopa®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinician and Patient Involvement Group (CAPIG) Meeting Summary
Download